search
Back to results

Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

Primary Purpose

Anal Fissure

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Minoxidil
Glyceryl trinitrate
Sponsored by
Mansoura University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anal Fissure focused on measuring anal fissure, minoxidil, glycreyl trinitrate

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients of both genders presenting with chronic anal fissure of more than 6 weeks in duration
  • Ageing between 18 and 65 years old.

Exclusion Criteria:

  • Pregnant patients.
  • Patients with recurrent anal fissure after previous sphincterotomy.
  • Patients with coexisting anorectal diseases or inflammatory bowel diseases.

Sites / Locations

  • Mansoura university hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Minoxidil

Glyceryl trinitrate

Arm Description

Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks

Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks

Outcomes

Primary Outcome Measures

Healing duration
the duration of time needed for complete healing defined as reepithelialization of the anoderm at the site of anal fissure

Secondary Outcome Measures

Anal pain
degree of relief of anal pain as measured by visual analogue scale (VAS) from 0 to 10 where 0 indicates no pain and 10 indicates the worst severe pain.

Full Information

First Posted
May 6, 2018
Last Updated
October 3, 2019
Sponsor
Mansoura University
search

1. Study Identification

Unique Protocol Identification Number
NCT03528772
Brief Title
Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure
Official Title
Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
May 10, 2018 (Actual)
Primary Completion Date
August 30, 2019 (Actual)
Study Completion Date
September 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This randomized trial aims to compare two topical treatments in the treatment of chronic anal fissure: minoxidil gel and glycreyl trintrate cream. The endpoint of the study is the duration of healing of anal fissure whereas secondary endpoints include adverse effects of each treatment and recurrence of anal fissure
Detailed Description
All participants who fulfill the inclusion criteria and give consent for participation in the trial and will be included and randomly assigned to either group I (5% Minoxidil gel) or group II (0.2% GTN cream) with a 1:1 allocation. Randomization will be carried out using online software (Research Randomizer Version 4.0 at https://www.randomizer.org). Patients will receive the topical agent in unlabeled red or blue containers. The code of each color will be known to a pharmacist who will not take any part in patients' care, follow-up, data collection/analysis or accessing outcomes of the study. The investigators will be blinded to the nature of content of each container and the outcome assessor will not be aware of the study nature. Interventions Eligible patients will be randomized into two equal groups: groups I will receive topical 5% Minoxidil gel (Minoxidil Forte 5% topical gel 60 gm; Pharmacare Egypt Co., Cairo, Egypt) and group II will receive topical 0.2% GTN cream (Nitoglycerine-Glycerile Tinitrade 0.2%, 30 gm; E.S.A.G Pharma Co., Cairo, Egypt). Both agents used in the study will be relabeled by a pharmacist who will not take any part in the study in terms of patients' care, follow-up, data collection/analysis or accessing outcomes. Both topical agents will be placed in identical containers of 60 gm and labeled with blue or red colors. The color code will remain undefined till the end of trial, data analysis, and interpretation of results except for the same pharmacist. The containers will be distributed to the patients by the outpatient's department nurse in the hospital. Patients will be advised to apply approximately 2 cm of the gel/cream (equal to 3 gm) on the perianal area three times per day for 4 weeks. The first dose of drugs will be given at home on the same day of the first visit. During the first visit, patients will be taught to self-administer the topical gel/cream. The patients will be instructed to take laxatives to avoid constipation and to avoid using other topical preparations during the study period. Follow-up Patients will be followed in the general and colorectal surgery outpatient clinics for a period of three months. Patients will be advised to visit the outpatient clinic every week for one month, then biweekly in the 2nd and 3rd months after starting treatment. In case of intolerable adverse events patients will be advised to visit the outpatient clinic at any other time point during the trial. At each visit the anal fissure will be inspected and the extent of healing will be assessed by a surgical resident who is unaware of the nature of the study. Patients will be asked about the improvement in their symptoms, particularly anal pain and bleeding. Pain will be measured at each visit by the Visual Analog Scale (VAS) ranging from no pain "0" to worst possible pain "10". Blood pressures will be measured and any decrease of > 15 mmHg from the basal pressure measured at the first visit will be considered significant. Adverse effects induced by the topical agents as itching, headache, palpitation, dizziness, excess perianal hair growth, and hypersensitivity reaction will be recorded. Itching will be assessed by 5-D pruritus scale. The continence state will be assessed using Wexner continence score.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anal Fissure
Keywords
anal fissure, minoxidil, glycreyl trinitrate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Minoxidil
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
Arm Title
Glyceryl trinitrate
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Minoxidil
Other Intervention Name(s)
Topical Minoxidil treatment
Intervention Description
application of minoxidil forte 5% gel three time per day on the anus for four weeks
Intervention Type
Drug
Intervention Name(s)
Glyceryl trinitrate
Other Intervention Name(s)
Topical GTN treatment
Intervention Description
application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
Primary Outcome Measure Information:
Title
Healing duration
Description
the duration of time needed for complete healing defined as reepithelialization of the anoderm at the site of anal fissure
Time Frame
two months
Secondary Outcome Measure Information:
Title
Anal pain
Description
degree of relief of anal pain as measured by visual analogue scale (VAS) from 0 to 10 where 0 indicates no pain and 10 indicates the worst severe pain.
Time Frame
three months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients of both genders presenting with chronic anal fissure of more than 6 weeks in duration Ageing between 18 and 65 years old. Exclusion Criteria: Pregnant patients. Patients with recurrent anal fissure after previous sphincterotomy. Patients with coexisting anorectal diseases or inflammatory bowel diseases.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sameh Emile, M.D.
Organizational Affiliation
Mansoura University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mansoura university hospital
City
Mansourah
State/Province
Dakahlia
ZIP/Postal Code
35516
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32028023
Citation
Emile SH, Abdel-Razik MA, Elshobaky A, Elbaz SA, Khafagy W, Shalaby M. Topical 5% minoxidil versus topical 0.2% glyceryl trinitrate in treatment of chronic anal fissure: A randomized clinical trial. Int J Surg. 2020 Mar;75:152-158. doi: 10.1016/j.ijsu.2020.01.143. Epub 2020 Feb 4.
Results Reference
derived

Learn more about this trial

Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

We'll reach out to this number within 24 hrs